Checkpoint Therapeutics, Inc.
CKPTNASDAQHealthcare
$4.26
+$0.00(+0.00%)
Market Cap$367723200
P/E Ratio—
52W High$4.5
52W Low$1.8
Checkpoint Therapeutics, Inc. (CKPT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CKPT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.04M | $0.10M | $0.19M | $0.27M | $1.07M |
| Cost of Revenue | $0.00M | $43.57M | $49.83M | $48.45M | $16.35M |
| Gross Profit | $0.04M | ($43.46M) | ($49.63M) | ($48.19M) | ($15.28M) |
| Gross Margin %(computed) | 100.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $36.15M | $43.57M | $49.83M | $48.45M | $16.35M |
| G&A Expenses | $20.06M | $8.69M | $8.30M | $8.54M | $7.92M |
| Total Operating Expenses | $56.22M | $52.25M | $58.52M | $56.99M | $24.27M |
| Operating Income | ($56.17M) | ($52.15M) | ($58.33M) | ($56.72M) | ($23.20M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01M | $0.08M | $0.16M | $0.05M | $0.12M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($56.24M) | ($51.85M) | ($62.62M) | ($56.67M) | ($23.08M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($56.24M) | ($51.85M) | ($62.62M) | ($56.62M) | ($23.08M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.42 | $-2.77 | $-7.09 | $-7.45 | $-4.13 |
| Wtd Avg Shares | 39.67M | 18.74M | 8.84M | 7.60M | 5.58M |
| EBITDA | ($56.17M) | ($52.15M) | ($53.88M) | ($56.49M) | ($23.20M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Checkpoint Therapeutics, Inc. data
About Checkpoint Therapeutics, Inc. (CKPT) Income Statement
Checkpoint Therapeutics, Inc. (CKPT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CKPT reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.06B) — a net profit margin of -137170.73%.
Frequently asked questions
CKPT · 4 questionsCheckpoint Therapeutics, Inc. (CKPT) reported revenue of $0.00B for 2024, down 60.2% year-over-year.
CKPT revenueCKPT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09